Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: Presentation of six case reports

Infection

Volumn 33, Issue 1, 2005, Pages 30-32

  Scotto, G ^a,b   Palumbo, E ^a   Fazio, V ^c   Cibelli, D C ^a   Saracino, A ^a   Angarano, G ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Hospital of Foggia ^*  (Italy)

^c Hospital of Foggia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; VIRUS RNA; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2B;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C VIRUS; HUMAN; INFECTION; MALE; PATIENT; RELAPSE; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; ACUTE DISEASE; BLOOD; DRUG EFFECT; GENETICS; HEPATITIS C; MIDDLE AGED;

ACUTE DISEASE; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 17844411452     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-4032-5     Document Type: Article

References (14)

1. Alter HJ, Seeff LB: Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
2. Mondelli MU: Natural history of hepatitis C virus infection. J Bio Reg Hom Ag 2003; 17: 128-132.
3. Orland JR, Wright TL, Cooper S: Acute hepatitis C. Hepatology 2001; 33: 321-327.
4. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, Pastore G: Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35: 104-113.
5. Alberti A, Boccato S, Vario A, Benvegnù L: Therapy of acute hepatitis C. Hepatology 2002; 36: S195-200.
6. Jaeckel E, Cornberg M, Wedemejer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP, German Acute Hepatitis C Therapy Group: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
7. Zeuzem S, Feinman SV, Rosenack J, Heathcote EJ, Lay MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl Med 2000; 343: 1666-1672.
8. Fried MW, Shiffman ML, Reddly KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
9. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group: A ramdomized double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
10. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
11. Rodriguez-Gomez SJ, de la Serna-Higuera C, Perez Villoria A, Martinez-Moreno J, Betancourt-Gonzalez A, Martin-Arribas MI: Peginterferon and ribavirin in a patient with acute hepatitis C. Am J Gastroenterol 2003; 98: 2102-2103.
12. Cariti G, Quaglia S, Meoli I, Veronese L, Audagnotto S, De Blasi T, Mancardi E, Raiteri R, Di Perri G: Is a 3-month course of treatment with peginterferon effective in acute HCV hepatitis? J Biol Regul Homeost Agents 2003; 17: 188-190.
13. Urbani S, Boni C, Missale G, Elia G, Cavallo C, Massari M, Raimondo G, Ferrari C: Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exibit functional differences in acute hepatitis B and C. J Virol 2002; 76: 12423-12434.
14. Licata A, Di Bona D, Schepis F, Shahied L, Craxi A, Camma C: When and how to treat acute hepatitis C? J Hepatology 2003; 39: 1056-1062.